Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases |
Ryu, Yon Ju
(Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine)
Chun, Eun Mi (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine) Lee, Soon Nam (Division of Hemato-Oncology, Department of Internal Medicine, Ewha Womans University School of Medicine) Shim, Sung Shin (Department of Radiology, Ewha Womans University School of Medicine) |
1 | Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306 DOI ScienceOn |
2 | Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in nonsmall- cell lung cancer. Drug Saf 2004;27:1081-1092 DOI ScienceOn |
3 | Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006;17:372-379 DOI ScienceOn |
4 | Teramoto S, Yamamoto H, Ouchi Y. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet 2003;361:1992-1993 |
5 | Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-2424 DOI ScienceOn |
6 | Topal NB, Oruc E, Gokalp G, Topal U. Atypical pulmonary metastases: radiologic appearances. Indian J Radiol Imaging 2007;17:181-185 DOI |
7 | Lee JC, Kim CH, Koh JS, Baek HJ, Choe DH. Lung cancer presenting as an asymptomatic pneumatocele. Intern Med 2008;47:1757-1758 DOI |
8 | Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 DOI ScienceOn |
9 | Barnardt P, du Toit J. The radiological appearance of metastatic cystic lesions. SA Journal of Radiology 2011:131-133 |
10 | Zee YK, Chin TM, Wong AS. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009;27:e145-e146 DOI |
11 | Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005;28:103-113 DOI |
12 | Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-424 DOI |